This study demonstrated that lncRNA-MALAT1 gets involved in NSCLC progression by targeting miR-202, indicating that MALAT1 may serve as a novel therapeutic target for NSCLC treatment. This evidence concerns the gene MALAT1 and non-small cell lung carcinoma.